uric acid sodium

Uric acid sodium is a potent and widely recognized antioxidant with the ability to scavenge oxygen free radicals, helping to maintain blood pressure stability and counteract oxidative stress. It effectively eliminates reactive oxygen species (ROS), such as singlet oxygen and peroxynitrite, and inhibits lipid peroxidation. Additionally, uric acid sodium is closely associated with the pathogenesis of gouty arthritis and the formation of calcium oxalate stones, and it can be used to induce hypertension models.

Sodium dodecyl sulfate(Sodium lauryl sulfate) is a pharmaceutical excipient that is biologically inactive and improves the stability, solubility and processability of pharmaceutical preparations.

Aminohippurate sodium (Sodium p-aminohippurate) is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.

Sodium Dodecanoate (Sodium Laurate) is the sodium salt of a medium-chain saturated fatty acid, commonly employed as a surfactant, emulsifier, and detergent. It may be utilised in establishing animal models for conditions such as Type 2 diabetes and vasculitis.

NLRP3-IN-46 (Compound 3k) activates the cholinergic anti-inflammatory pathway involved in neuro-immune modulation, thereby inhibiting the activation of the NLRP3 inflammasome. Furthermore, NLRP3-IN-46 suppresses the production of IL-1β in THP-1 cells induced by Uric acid sodium, making it relevant for research in gouty arthritis.

URAT1 inhibitor11 (Compound 7) is a potent URAT1 inhibitor, exhibiting an IC50 of 0.18 μM. It effectively reduces uric acid levels in zebrafish with hyperuricemia induced by Potassium oxonate and Xanthinesodium salt.

Lesinurad sodium (RDEA594 sodium) is a selective inhibitor of uric acid reabsorption and is used in the study of cardiovascular diseases.

Cyclopenthiazide (Cyclomethiazide) is a thiazide diuretic used to treat hypertension and heart failure. It decreases the excretion of calcium ions and uric acid and increases the excretion of sodium and potassium ions.

Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine (T20615) is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1

3-Methyl-2-oxovaleric acid sodium is a degradation product of isoleucine. It serves as a biomarker for mustard airway disease (MAD) and uric acid stones.